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By presenting immunogenic peptides at the cell surface, major histocompatibility complex (MHC) class II molecules play a key role in
the control of adaptive immune responses. Whether expressed constitutively or induced by interferon-g, expression of MHC class II
molecules is regulated via coactivator class II transactivator (CIITA); moreover, suppression of their expression is one mechanism by
which cancer cells escape host immunity. In this study, we surveyed the relationship between the expression of one MHC class II
antigen, HLA–DR, and its coactivators in a group of haematopoietic cell lines, and explored the role of the aberrant DNA
methylation in silencing HLA-DR expression. Among 26 cell lines studied, HLA-DR expression was lost from eight T-cell and two
myeloid leukaemia cell lines, and this loss was closely associated with suppression of CIITA-PIV expression. Notably, nine of the 10
cell lines that lost CIITA-PIV expression showed methylation of the gene’s 50 CpG island. Thus, DNA methylation is believed to inhibit
the expression of MHC class II molecules in haematopoietic tumour cells by silencing its coactivator, CIITA-PIV. Furthermore,
methylation of CIITA-PIV was detected in seven of 32 primary acute myeloid leukaemia specimens, indicating that epigenetic
alteration is not a cell line-specific phenomenon. Collectively, these data suggest that, by suppressing expression of MHC class II
molecules, epigenetic inactivation of CIITA provides a survival advantage to a subset of haematopoietic tumours.
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By presenting immunogenic peptides at the cell surface, major
histocompatibility complex (MHC) class II molecules play a key
role in the control of adaptive immune responses (Cresswell,
1994). Moreover, increasing evidence indicates that the ability of
CD4þ T-cells to recognise tumour cells by the MHC class II
molecules on their surface enables CD4þ T-cells to contribute to
antitumour immune responses; consequently, the absence of MHC
class II molecules likely diminishes the antitumour activity of
CD4þ T-cells (Ossendorp et al, 2000; Wang, 2001). Constitutive
expression of MHC class II is limited to specific immune cell types,
such as antigen-presenting and dendritic cells. However, their
expression can be induced in nonimmune cells that do not
constitutively express them by interferon-g (IFN-g).
Expression of MHC class II molecules is also regulated by class
II transactivator (CIITA) (Mach, 1999), which does not bind to
DNA but acts as a coactivator, interacting with DNA-binding
transcription factors such as regulatory factor X (RFX) family, NF-
Y and CREB (Scholl et al, 1997; Zhu et al, 2000). Transcription of
CIITA is regulated by CIITA promoters (CIITA-P) I–IV, each of
which directs the expression of a unique first exon (Muhlethaler-
Mottet et al, 1997): CIITA-PI is active primarily in dendritic cells
and murine macrophages (Waldburger et al, 2001); CIITA-PII has
been identified only in human cells, and its function remains
unknown; CIITA-PIII is primarily responsible for directing
constitutive expression of CIITA in B cells, and can drive CIITA
expression after IFN-g stimulation in endothelial cells, fibroblasts
or melanocytes (Piskurich et al, 1998; Deffrennes et al, 2001), and
CIITA-PIV is a major regulator of IFN-g-inducible expression of
CIITA (Muhlethaler-Mottet et al, 1997).
Haematopoietic tumours often show genetic alterations such as
nonrandom chromosomal translocations and gene deletion or
amplification. In addition, epigenetic modifications of the DNA,
which do not alter the sequence code, are now recognised to
contribute to the malignant phenotype. For instance, somatic
changes in the methylation of CpG dinucleotides commonly occur
during the pathogenesis of human tumours (Jones and Baylin,
2002). Among haematopoietic tumours, aberrant methylation of
promoter-associated CpG islands (CGIs) in oestrogen receptor,
p16INK4A, p15INK4B, p73, p57KIP2 and DAP kinase has been
observed in acute lymphocytic leukaemia (ALL), acute myeloid
leukaemia (AML), malignant lymphoma and multiple myeloma
(Herman et al, 1997; Katzenellenbogen et al, 1999; Garcia-Manero
et al, 2002a,b; Li et al, 2002). Methylation-mediated silencing of
Received 3 August 2003; revised 24 November 2003; accepted 27
November 2003
*Correspondence: M Toyota; E-mail: mtoyota@sapmed.ac.jp
British Journal of Cancer (2004) 90, 844–852
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ygenes involved in immune system function has not been reported
in haematopoietic tumours, however.
It is now known that some haematopoietic tumour cells do not
express the MHC class II antigen HLA-DR (Kraiba et al, 1989;
Wetzler et al, 2003), though the reason why remains unclear. In the
present study, we examined expression HLA-DR and coactivators
of MHC class II molecules, as well as the effects DNA methylation
and histone deacetylation, in a group of human haematopoietic
tumour cell lines. Our data suggest that aberrant methylation and
histone deacetylation of the region around the transcription start
site of CIITA-PIV are closely associated with the absence of IFN-g-
induced expression of CIITA-PIV, which in turn causes absence of
HLA-DR induction in haematopoietic tumour cells.
MATERIALS AND METHODS
Cell lines and specimens
DNA and RNA were prepared from eight T-cell ALL cell lines
(Jurkat, Molt4, CCRF-HSB2, CCRF-CEM, SupT1, PEER, TALL1,
Molt3), six B-cell ALL cell lines (BALL1, CCRF-SB, TOM1, LB804,
NALM21, NAGL-1), five multiple myeloma cell lines (HS-Sultan,
KMS-12PE, RPMI8226, KHM-1B, U266B1), four myeloma cell lines
transformed by Epstein–Barr virus (TAPC, IM9, KR12,
RPMI1788), one malignant lymphoma cell line (Raji) and two
myeloid leukaemia cell lines (K562, KG1). TOM1, LB804 and
NALM21 were kindly provided by Dr Ken Kondo of Hokkaido
University, Dr Pierre G Coulie of Ludwig Institute for Cancer
Research and Dr Yoshinobu Matsuo of Hayashibara Biochemical
Labs, respectively. Other cell lines were obtained from the
American Type Tissue Culture Collection or the Japanese
Collection of Research Bioresources (Tokyo, Japan). In addition,
32 primary acute myeloid leukaemia specimens used for methyla-
tion analysis were described previously (Toyota et al, 2001). To
promote the expression of MHC class II molecules, cells were
treated with 100Uml
 1 of IFN-g for 48h prior to their harvest.
DNA was extracted using the phenol/chloroform method. Total
RNA was extracted using Isogen (Nippon Gene, Japan), according
to the manufacturer’s instructions.
Bisulphite treatment
For bisulphite-PCR, genomic DNA was initially treated with
sodium bisulphite (Sigma), as described previously (Clark et al,.
1994), after which 2-mg samples were denatured for 10min in 2 M
NaOH at 371C before the addition of 30m1o f1 0m M hydroquinone
(Sigma Chemical Co. St Louis, MO, USA) and 520mlo f3M sodium
bisulphite (pH 5.0). The mixture was then incubated for 16h at
501C. The resultant modified DNA was purified using a Wizard
DNA Purification System (Promega, Madison, WI, USA), after
which it was again treated with NaOH and precipitated. Finally,
the DNA precipitate was resuspended in 20ml of water and stored
at –201C until used.
Combined bisulphite restriction analysis (COBRA) and
bisulphite sequencing
To examine the methylation status of CIITA, COBRA, a
semiquantitative analysis of methylation, was carried out as
described previously (Xiong and Laird, 1997). Primers for COBRA
were designed based on the nucleotide sequences obtained from
Genbank (AL591852). Primer sequences are as follows: CII-
TAGM1-F, 50-GTAGTTGGGATGTTATTTTTGATAAAG-30; CIITA-
GM1-R, 50-TCTCCCTCCCRCCAACTCT-30; CIITAGM2-F, 50-GGT-
RT
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Figure 1 Expression of HLA-DR in haematopoietic tumour cell lines. RT-PCR was carried out using cDNA prepared from haematopoietic tumour cell
lines treated with either mock or 100Uml
 1 of IFN-g for 48h. GAPDH was amplified to confirm the integrity of the cDNA. Cell lines and cell types are
shown on the top.
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CRAAACTCTAAACAC-30. The PCR products were digested with
restriction enzymes that cleave CpG sites retained because of
methylation. After ethanol precipitation, the DNA was subjected to
3% agarose gel electrophoresis and stained with ethidium bromide.
For bisulphite sequencing, the PCR products were amplified using
primers CIITA-GM1F and CIITA-SEQR, 50-ACAATCT-
CRAAACCTCRATTCTC-30, and cloned into pCR4 vector using a
TOPO-TA cloning Kit (Invitrogen), after which the plasmid DNA
was purified using a PI system (Kurabo, Tokyo, Japan). Sequen-
cing was carried out using a BigDye Terminator Kit and an ABI
3100 DNA sequencer (Applied Biosystems).
RT–PCR
The RNA (5mg) was reverse-transcribed using Superscript II
(Invitrogen) to prepare first-strand cDNA. Expression of CIITA-PI,
PIII and PIV and HLA-DR was assessed using the following
primers: CIITAPI-F, 5’-ACTTCCAGGCCATCCTGACT-3’; CIITA-
PI-R, 5’-GTAGAGGCACAGGGGGTCAGC-3’; CIITAPIII-F, 5’-
TTCCTACACAATGCGTTGCC-3’; CIITAPIII-R, 5’-TGCTGAACT-
GGTCGCAGTTGATGG-3’; CIITAPIV-F, 5’- AGACTTGCCGCGG-
CCCCAGAG-3’; CIITAPIV-R, 5’-GTAGAGGCACAGGGGGTCAGC-
3’; HLADR-F, 5’-GCCAACCTGGAAATCATGACA-3’; HLADR-R,
5’-AGGGCTGTTCGTGAGCACA-3’; RFX5-F, 5’-AACCACCTG-
GAAGAGCACACTGAC-3’; RFX5-R, 5’-CCAGGCAGGGGTGGCA-
TAGA-3’; RFXAP-F, 5’–GTGCAAGAAACACCGCAACAAGAT-3’;
RFXAP-R, 5’–CTGCTGTTGTCTTTGCTCCAAAACT-3’; RFXB-F,
5’–CTCCCTGAAGCACTCCACCACTC-3’; RFXB-R, 5’–AGCAG-
GAAGCGAACGGTCTCAA-3’; RFXANK-F, 5’–AGACCTCATCCA-
GACCCAGCAGAC-3’ and RFXANK-R, 5’–CTCGCTGCCGGTT-
GGTGAGA-3’. Controls consisted of RNA treated identically, but
without the addition of reverse transcriptase (RT ). The integrity
of the cDNA was confirmed by amplifying GAPDH as described
previously (Suzuki et al, 2002). Samples (10ml) of the amplified
products were then subjected to 2.5% agarose gel electrophoresis
and stained with ethidium bromide.
Flow cytometry
Cells were incubated for 60min at 41C, first with anti-HLA-DR
monoclonal antibody L243 (ATCC) and then with affinity-purified
fluorescein-conjugated goat anti-mouse IgGþIgM (Kirkegaard
and Perry Laboratories, Gaithersburg, MD, USA), after which they
were analysed in a FACScan flow cytometer (BD Biosciences). At
least 30000 viable cells were studied in each condition. The data
were analysed using CELLQUEST software (BD Biosciences).
Table 1 Expression and methylation status of HLA-DR and various types of CIITA in haematopoietic tumour cell lines
Expression
HLA-DR CIITA-PI CIITA-PIII CIITA-PIV
Methylation
Cell lines Mock IFN-c Mock IFN-c Mock IFN-c Mock IFN-c CIITA-PIV
B-cell ALL
BALL 1 None +++ None None 0-+ + None +++ Unmethylated
CCRF-S8 +++ +++ None None + + +++ +++ Unmethylated
TOM 1 None +++ None None None + None +++ Unmethylated
LB804ALL +++ +++ None None + + +++ +++ Unmethylated
NALM21 (Ph1+) +++ +++ None None + + +++ +++ Unmethylated
NAGL-1 +++ +++ None None + + +++ +++ Unmethylated
Myeloma
KMS12-PE +++ +++ None None None None +++ +++ Unmethylated
RPMI8226 + +++ None None None None + +++ Unmethylated
HS-sultan +++ +++ None None None None +++ +++ Unmethylated
KHM-1B +++ +++ None None None None +++ +++ Unmethylated
U266B1 +++ +++ None None None None +++ +++ Unmethylated
Mature B cell
TAPC +++ +++ None None None None +++ +++ Unmethylated
RPMI1788 +++ +++ None None + + +++ +++ Unmethylated
IM9 +++ +++ None None + + +++ +++ Unmethylated
KR12 +++ +++ None None + + +++ +++ Unmethylated
T-cell ALL
Jurkat None None None None None None None None Methylated
Motl4 None None None None None None None 0-+ Methylated
CCRF-HSB2 None None None None None None None 0-+ Methylated
CCRF-CEM None None None None None None None 0-+ Methylated
SupT1 None None None None None None None None Methylated
PEER None None None None None None None 0-+ Methylated
TALL1 None None None None None None None None Methylated
Molt3 None None None None None None None None Unmethylated
Burkitt’s
Raji +++ +++ None None + + +++ +++ Unmethylated
Myeloid
K562 None None None None None None None + Methylated
KG-1 None None None None None None None None Methylated
+++: strong expression. +: weak expression. None: no expression.
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Cells (1 10
6) were plated on 10-cm dishes, incubated for 24h,
and then treated with mock or 100Uml
 1 IFN-g for 48h. The cells
were then exposed to formaldehyde, and chromatin was immuno-
precipitated for 16h at 41C using antiacetylated histone H3
antibodies (Upstate Biotechnologies, Lake Placid, NY, USA). After
immunoprecipitation, the DNA was recovered using agarose
beads, incubated with Proteinase-K at 451C for 1h, purified using
the phenol/chloroform method, and precipitated with ethanol.
PCR was carried out with approximately 1/100 of the immuno-
precipitated DNA using SYBR Green sequence detection reagents
(Applied Biosystems) in a solution containing l00ng of DNA, 25ml
of SYBR Green PCR Master Mix and 2.5pmol of each primer. The
primers used were 50-ACAAGCTCCCTGCAACTCAG-30 (CIITA-
ChIP-F) and 50-CCACCACGTGCTTTATCAGA-30 (CIITAChIP-R).
In addition, the 50 region of GAPDH was amplified as an internal
control. The PCR cycling protocol entailed one cycle at 951C for
5min and 40 cycles at 951C for 30s and 601C for 1min. Fluorescent
signals were detected using an ABI 7000 Prism 7000 (Applied
Biosystems), and the accumulation of PCR product was measured
in real time as the increase in SYBR green fluorescence. Data were
analysed using ABI Prism 7000 SDS Software (Applied Biosys-
tems). Standard curves relating the initial template copy number to
the fluorescence and amplification cycle were generated using the
amplified PCR product as a template, and were then used to
calculate the DNA copy number in each sample. Ratios of the
intensities of the CIITA and GAPDH signals served as relative
measures of the histone acetylation level of CIITA in each cell line.
RESULTS
Expression of HLA-DR in haematopoietic tumour cell lines
We initially examined the expression of HLA-DR in a group of
haematopoietic tumour cell lines, with or without IFN-g treatment
(Figure 1, summary in Table 1). RT–PCR analysis of 26 cell lines
showed that 13 expressed HLA-DR constitutively; three expressed
it following induction with interferon-g; and 10 did not express it
at all. None of the T-cell leukaemia cell lines expressed HLA-DR,
while cell lines established from B-cell ALL, mature B-cells and
Burkit lymphoma all showed constitutive or IFN-g-inducible HLA-
DR expression.
Flow-cytometric analysis showed HLA-DR protein to be present
at the surface of cells that express HLA-DR mRNA constitutively
(Figure 2, KHM1B) or after induction with IFN-g (RPMI8226).
Conversely, surface expression of HLA-DR was not detected in
cells that did not express HLA-DR mRNA (TALL1 and PEER),
which indicates that the absence of surface HLA-DR protein was
caused by loss of gene transcription, rather than by post-
transcriptional alteration.
Expression of the transactivator of MHC class II in
haematopoietic tumour cells
Bare lymphocyte syndrome (BLS) is a severe immunodeficiency
caused by the absence of MHC class II molecules (Klein et al,
1993). Patients with this syndrome carry a defect in the genes
encoding the components of the RFX complex and CIITA (Steimle
et al, 1993; Villard et al, 1997; Masternak et al, 1998; Nagarajan
et al, 1999). To determine the role of RFX and CIITA genes in the
suppression of HLA-DR expression, we carried out RT–PCR with
a group of haematopoietic tumour cell lines that either did or did
not express HLA-DR (Figure 3A and B). We found ubiquitous
expression of all the four RFX subunits in T-cell lines, irrespective
of whether they expressed HLA-DR, and therefore excluded RFX
inactivation as a cause of the MHC class II suppression (Figure 3B).
When we then examined the expressions of CIITA-PI, CIITA-
PIII and CIITA-PIV in each cell line (Figure 3A and Table 1), we
found that, as expected, CIITA-PI mRNA was not expressed in any
of the haematopoietic cells studied. T-cell ALL and myeloid
leukaemia cell lines showed complete suppression of both CIITA-
PI and CIITA-PIII, five cell lines (Molt-4, CCRF-HSB2, CCRF-CEM,
PEER and K562) expressed low or negligible levels of CIITA-PIV,
and five (Jurkat, SupT1, TALL1, Molt-3, and KG1) did not express
it at all. Class II transactivator-PII was not examined, as its
function remains unknown.
Most of the cell lines derived from multiple myeloma showed
constitutive expression of HLA-DR, which correlated with CIITA-
PIV expression. Class II transactivator-PIII was expressed in all
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Figure 2 Cell surface expression of the HLA-DR protein in haematopoietic tumour cell lines. Cell lines were treated with either mock or 100Uml
 1 IFN-
g for 48h, after which HLA-DR expression was analysed by flow cytometry.
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ytransformed B-cells, but not in multiple myeloma cells (data not
shown). One cell line, RPMI 8226, showed enhanced expression of
HLA-DR and CIITA-PIV. This is thought to reflect both the IFN-g
inducibility and CIITA-PIV dependence of HLA-DR expression in
these cells. Thus, all of the cell lines from B-cell lineages showed
strong constitutive and/or inducible HLA-DR expression.
DNA methylation of CIITA-PIV
We evaluated the possible involvement of DNA methylation in
the silencing of the CIITA-PIV gene, using COBRA (Figure 4).
Cell lines derived from T-cell ALL showed varying degrees of
methylation: four (SupT1, Molt-4, PEER and TALL1) showed
strong DNA methylation; three (Jurkat, CCRF-HSB2 and CCRF-
CEM) showed weak-to-moderate methylation and one (Molt-3)
showed no methylation. By contrast, most cell lines of B-cell
lineage, including multiple myeloma, show no CIITA-PIV methy-
lation; two (TOM1 and RPMI8226) showed slight methylation. Two
myeloid leukaemia cell lines (K562 and KG1) also showed
methylation.
We then carried out DNA sequence analysis to assess the
pattern of methylation in the CIITA-PIV locus using six
cell lines, selected because they showed different degrees of
methylation (Figure 5). Cell lines derived from T-cell ALL
that do not express CIITA-PIV showed varying levels of DNA
methylation in the region analysed. By contrast, no methylation
was found in B-cell ALL (BALL1 and CCRF-SB). Careful
examination of the pattern of methylation within the loci suggested
that upstream regions are more densely methylated than down-
stream ones.
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Figure 3 Expression of MHC class II transactivator in haematopoietic tumour cell lines. (A) RT–PCR analysis of CIITA expression in haematopoietic
tumour cell lines. cDNA from cells treated with either mock or IFN-g for 48h was amplified using primers that specifically amplify CIITA-PIV. The cell lines
analysed are shown on the top. (B) RT–PCR analysis of RFX-5, RFX-AP, RFX-ANK and RFX-B in haematopoietic tumour cell lines.
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CIITA-PIV, two methylated cell lines (Jurkat and CEM) were
treated with a methyltransferase inhibitor, 5-aza-dC, and/or IFN-g.
Although treating the cell lines with either 5-aza-dC or IFN-g did
not restore expression of either CIITA or HLA-DR, combined
treatment with both 5aza-dC and IFN-g restored expression of
both CIITA-PIV and HLA-DR (Figure 6).
Histone deacetylation associated with DNA methylation-
dependent CIITA gene silencing
Deacetylation of histone is known to be associated with DNA
methylation-dependent gene silencing (Nguyen et al, 2001; Suzuki
et al, 2002). To determine the histone acetylation status in the
CIITA locus, we carried out ChIP assays using antiacetylated
histone H3 antibody (Figure 7). Overall, there was an inverse
correlaion between DNA methylation and histone acetylation in
CIITA-PIV. In unmethylated cell lines, levels of histone acetylation
were high in the CIITA promoter region. In BALL1 and TOM1
cells, moreover, histone acetylation was induced by treatment with
IFN-g, indicating a role for histone acetylation in gene expression.
By contrast, levels of histone acetylation remained low among cell
lines that showed CIITA methylation, even after treatment with
IFN-g.
Aberrant methylation of CIITA-PIV in primary AMLs
To determine whether methylation of CIITA-PIV might be a
feature of primary leukaemia, we carried out COBRA analyses
using DNA from a group of AML specimens. Aberrant methylation
of CIITA-PIV was detected in seven of the 32 (22%) cases studied
(Figure 8), whereas no methylation was detected in normal
lymphocytes or bone marrow (data not shown). Thus, methylation
of CIITA-PIV is not a cell line-specific phenomenon.
DISCUSSION
To explore the cause of the absence of MHC class II molecules in
haematopoietic tumour cells, we examined the relationship
between expression of HLA-DR and its co-activators (CIITA and
RFX complex). Our results indicate that the CIITA-PIV expression
is suppressed by DNA methylation of its 50 CpG island, which in
turn leads to suppression of HLA-DR expression.
DNA methylation is known to be involved in the regulation of
CIITA and MHC gene expression in several tumour cell types,
including trophoblast-derived cells, a subset of lymphoma cells,
and squamous cell carcinoma (Morris et al, 2000; Nie et al, 2001;
Murphy et al, 2002; Moreau et al, 2003). Our results suggest that
DNA methylation of CIITA-PIV is also a major cause of HLA-DR
suppression in haematopoietic tumour cells, especially those
derived from T-cells and myeloid cells. One exception was Molt-
3 T-cell leukaemia cells, which expressed no CIITA-PIV, even
though the promoter region of the gene showed no methylation.
Further study will be necessary to clarify whether epigenetic
mechanisms other than DNA methylation – for example, histone
modification (Jenuwein and Allis, 2001) – played a role in the
silencing CIITA-PIV expression in those cells. In contrast to T-
cells, most of those derived from B-cells showed strong
constitutive or inducible HLA-DR expression. One plausible
explanation is that constitutive expression of CIITA provides
access to transcription factors that protect the CpG island from
DNA methylation.
Although expressions of CIITA-PIV and HLA-DR were mutually
exclusive, we did not formally exclude the possibility of an
association between other CIITA promoters (e.g., CIITA-PIII) and
the absence of MHC class II, and, indeed, CIITA-PIII can drive
CIITA expression after IFN-g stimulation in a number of cell types,
including endothelial cells, fibroblasts and melanocytes. But while
the extent to which deregulation of CIITA-PIII is involved in the
silencing of the HLA-DR gene awaits further investigation, the fact
that the 50 region of CIITA-PIII does not contain a CpG island
makes it unlikely that DNA methylation plays a role in gene
silencing.
MHC class II expression has been shown to be inversely related
to tumorigenicity and directly related to immunogenicity of mouse
L1210 lymphoma clones (Fuji and Iribe, 1986). Indeed, it is now
known that the loss of MHC molecules is one of the mechanisms
by which cancer cells escape host immunity (Garrido and Algarra,
2001). That most cells of B-cell lineage express HLA-DR, while
those of T-cell lineage do not, may be one of the reasons for the
difference in prognosis between B-cell and T-cell malignancies –
that is, leukaemias or lymphomas involving B-cell lineage generally
have better prognoses than their T-cell counterparts. It is therefore
noteworthy that epigenetic modifications are reversible, which
may make them an effective target for therapeutic intervention.
Although intensive chemotherapy remains the therapeutic main-
stay for acute leukaemia, long-term cure rates with chemotherapy
alone remain at approximately 50%, creating an urgent need for
better therapies. Clinical trials are currently underway to study the
effects of DNA methylation inhibitors in both haematological
malignancies (Lubbert, 2000) and solid tumours (Momparler et al,
2000).
Our data suggest that drugs able to reverse aberrant
epigenetic modification harbour a therapeutic potential related
to their ability to reactivate silenced MHC class II expression. In
that regard, expression of HLA-G, an MHC class I molecule, was
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ypreviously re-established using a demethylating agent or histone
deacetylase inhibitors (Moreau et al, 2003). Similar results might
be expected in certain MHC class II-negative haematologic
malignancies (e.g., T-cell ALL), perhaps leading to improved
prognoses. Other genes that show aberrant DNA methylation of
the promoter-associated CGI in T-cell ALL include p15, p73 and C-
ABL (Garcia-Manero et al, 2002a,b). Similarly, an association may
exist between CIITA-PIV methylation and poorer clinical prog-
nosis. Further evaluation of this association would seem
warranted.
The methylation around the transcription start site, which
silenced CIITA-PIV gene expression, was in turn inversely related
to histone acetylation, indicating a possible role for histone
deacetylation in the gene silencing. This would be consistent with
the findings of Morris et al (2002), who reported histone
acetylation to be involved in the transcriptional regulation of
CIITA.
Most multiple myeloma cell lines showed strong constitutive
expression of HLA-DR. B lymphocytes constitutively express MHC
class II genes; however, that expression is downregulated as they
differentiate into plasma cells (Halper et al, 1978; Dellabona et al,
1989), reflecting diminished CIITA gene transcription (Silacci et al,
1994). Unexpectedly, myeloma cells, the malignant counterpart of
plasma cells, showed constitutive MHC class II expression.
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Figure 6 Restoration of IFN-g-induced expression of CIITA and HLA-
DR in methylated cell lines. RT–PCR was carried out using cDNA
prepared from haematopoietic tumour cell lines treated with either mock,
100U of IFN-gml
 1 of for 48h, 1mM 5-aza-dC for 72h or 1mM 5-aza-dC
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Figure 7 Real-time quantitative PCR analysis of acetylation of the CIITA
locus in haematopoietic tumour cell lines. Chromatin immunoprecipitation
analysis assays were carried out using antiacetylated histone H3 antibody
after treatment with interferon-g or mock. Four cell lines that express
CIITA (RPMI8226, KHM1B, BALL1 and TOM1) and two cell lines that do
not express (PEER and SupT1) were examined. Fluorescent signals were
quantitated using an ABI7000 analysis system (Applied Biosystems). Bars
depict the ratios of the intensities of the CIITA and GAPDH signals.
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cells, they regain constitutive MHC class II expression. None-
theless, CIITA-PIII, which normally directs constitutive MHC class
II expression in B-cells, remained suppressed in all myeloma cell
lines. In this case, constitutive HLA-DR expression was dependent
on CIITA-PIV expression. This is of particular interest to us,
because the dependence of constitutive MHC class II expression on
CIITA-PIV has not been reported previously. As a consequence,
multiple myeloma cells showed expression of HLA-DR with no
methylation in CIITA-PIV, perhaps making them a good target for
CD4þ T-cells, which recognise antigen restricted by MHC class II
molecules.
In summary, we have shown that the aberrant methylation of
CIITA-PIV is associated with the silencing of CIITA-PIV and HLA-
DR expression in T-cell ALL. As this epigenetic change may enable
the cells escape from the host immune system, it may be a useful
indicator of prognosis. Moreover, drugs that reverse such aberrant
methylation would seem potentially useful in the treatment of T-
cell ALL.
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